Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?
Thrombosis and Haemostasis · 08.07.2026
DOI: 10.1055/a-2901-6693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 08.07.2026. Verfasst von Riccardo Prezzavento und 1 weiteren Autor:innen. Beteiligte Einrichtung: A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Cardiology Unit, Italy, Italy, Catania.
Abstract (Originalsprache)
AbstractPrasugrel and ticagrelor are potent oral P2Y12 inhibitors that carry a Class I recommendation for patients with acute coronary syndromes undergoing percutaneous coronary intervention, providing faster and more consistent platelet inhibition than clopidogrel. Despite identical guideline positioning, the optimal choice between the two agents has long remained unsettled, largely because head-to-head randomized data were scarce and the agents were assumed to be clinically interchangeable. That assumption is now substantially challenged by two large randomized trials (ISAR-REACT 5 and TUXEDO-2) whose convergent findings consistently point in the same direction. Here, we argue that the accumulated pharmacological and clinical evidence builds a coherent, mechanistically grounded case for the preferential use of prasugrel in appropriately selected patients, and that persisting therapeutic inertia against this drug is no longer scientifically defensible.
Autor:innen und Institutionen
- A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Cardiology Unit, Italy, Italy, Catania.
ORCID-Profile: Davide Capodanno
Zitieren
APA
Prezzavento, R., & Capodanno, D. (2026). Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2901-6693
Vancouver
Prezzavento R, Capodanno D. Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2901-6693
BibTeX
@article{Prezzavento2026,
author = {Prezzavento, Riccardo and Capodanno, Davide},
title = {Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2901-6693}
}
EUVIMED